Bristol-myers Squibb Compnay

Other

Merck + Co., Inc.

Padlock Therapeutics, Inc.

Michael Frederick Parker

Daniel J Keavy

Graham Johnson

Ronald J Mattson

Joanne J Bronson

Katherine S Takaki

John E Macor

Carl P Bergstrom

Joseph P Yevich

Fukang Yang

Kevin W Gillman

Andrew P Degnan

Lawrence R Marcin

John D Catt

Robert A Mate

Yonghua Gai

Lawrence B Snyder

Pratik Devasthale

Guohua Zhao

Xiaojun Han

David W Smith

Xiang-Yang Ye

Rita Civiello

Kumaravel Selvakumar

Suresh Dhanusu

Brett T Watson

George N Karageorge

Swanee E Jacutin-Porte

Hong Huang

Leatte R Guernon

Katharine E McElhone

Palanikumar Balasubramanian

Milind Deshpande

Gnanasambandam Kumaravel

Benito Munoz

Prasad V Chaturvedula

Rajesh Devraj

Owen Brendan Wallace

Heather Tye

Pui Leng Loke

Haiquan Fang

Cristina Lecci

Charles P Sloan

Matthew D Hill

Laura Gleave

Mirco Meniconi

Carl Leslie North

Mark Peter Ridgill

Elise Gadouleau

Shelley Anne Parrott

Jordan Palfrey

Edward Beaumont

Philip Stephen Kerry

Nat Monck

Adrian Kotey

Thomas Krulle

Emma I Parker

Lee Bowles

Steve Bromidge

Sophie Cooper

Darrell Maxwell

Mark V Silva

Katharin E McElhone

Kumar Srinivasan

Wai Yu Lau

Henry Hui Wang

Steve Brombridge

Pui Loke

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to α-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of α-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

3-substituted propionic acids as αV integrin inhibitors

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system.

Oxazolidinones as modulators of MGLUR5

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to &#x3b1;-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of ay-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions. 

3-substituted propionic acids as &#x3b1;V integrin inhibitors

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Bicyclic inhibitors of PAD4

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, agonists and partial agonists for the mGluR5 receptor and may be useful for the treatment of various disorders of the central nervous system. 

Oxazolidinones as modulators of mGluR5

There is provided a series of novel &#x3b1;-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R, Rand Rare defined herein, which are inhibitors of &#x3b2;-amyloid peptide (&#x3b2;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.

&#x3b1;-(N-sulfonamido)acetamide derivatives as &#x3b2;-amyloid inhibitors

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

Substituted heterocyclic ethers and their use in CNS disorders

A series of N-alkanol-N-phenyl benzenesulfonamide and related derivatives of the Formula I are disclosed,wherein R, R, R, X, and Y are defined herein. The compounds are inhibitors of &#x3b2;-amyloid peptide (&#x3b2;-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions characterized by aberrant extracellular deposition of amyloid. Pharmaceutical compositions and methods of treatment are also disclosed.

Antiamyloid phenylsulfonamides: N-alkanol derivatives

In accordance with the present invention, there is provided a novel class of sulfonamide compounds. Compounds of the invention contain a core sulfonamide group. Variable moieties connected to the sulfur atom and nitrogen atom of the sulfonamide group include substituted or unsubstituted hydrocarbyl moieties, substituted or unsubstituted heterocycle moieties, polycyclic moieties, halogen, alkoxy, ether, ester, amide, sulfonyl, sulfonamidyl, sulfide, carbamate, and the like. Invention compounds are capable of a wide variety of uses. For example sulfonamide compounds can act to modulate production of amyloid &#x3b2; protein and are useful in the prevention or treatment of a variety of diseases. Pharmaceutical compositions containing invention compounds are also provided. Such compositions have wide utility for the prevention or treatment of a variety of diseases.

Sulfonamide compounds and uses thereof

Novel derivatives of benzopyran are provided which are useful as melatonergic agents.

Benzopyran derivatives as melatonergic agents

A plurality of ice cream cone nesting sites (14) are formed on the base wall (12,12') of a carrier (10,10'). Each nesting site is formed by a nesting wall configured as a truncated cone with its diameter decreasing as the distance from the base wall increases. The bottom wall is spaced above a supporting surface on which the carrier may be placed by feet (22,22') extending downwardly from the bottom wall to facilitate grasping and handling. A lip (28) may be formed around the outer perimeter of the bottom wall to provide spill containment and to enhance gripping of the carrier.

Carrier for ice cream cones and the like

Novel derivatives of benzodioxa alkylene ethers are provided which are useful as melatonergic agents.

Benzodioxa alkylene ethers as melatonergic agents

Growing community of inventors

Higganum, CT, United States of America

Michael Frederick Parker